pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
471
stories
10d
Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launch
fiercebiotech
10d
Recon: FDA shelves commissioner's voucher program; Eli Lilly gets first GLP-1 weight-loss pill approved in China
raps
10d
Why a fresh approach to targeting G protein-coupled receptors could treat a rare eye cancer
fiercebiotech
11d
How Hims plans to reinvigorate its business
endpoints
11d
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
stat
11d
STAT+: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more
stat
11d
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
biopharma dive
11d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
12d
STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
stat
12d
STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care
stat
12d
Oura to acquire AI virtual primary care partner Counsel Health for $625M
fiercebiotech
12d
STAT+: GLP-1s are given an FDA warning for rare eye condition risk
stat
12d
STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
stat
12d
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
biospace
12d
STAT+: PepGen says early trial for muscular dystrophy drug looks promising
stat
12d
STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke
stat
13d
FDA orders GLP-1 drugmakers to warn of rare eye disease
endpoints
13d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
13d
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
biospace
13d
STAT+: Heart association meeting’s readout is trending ‘neutral’
stat
13d
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
endpoints
13d
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
stat
13d
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
fiercebiotech
13d
STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
stat
13d
MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
fda medwatch
16d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
17d
#AASLD26: Merck unwraps biopsy data for MASH drug it got from South Korea's Hanmi
endpoints
17d
MetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver disease
fiercebiotech
18d
Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
biopharma dive
18d
Amgen starts MariTide autoinjector study as pivotal readouts approach
biospace
← prev
page 2 of 16
next →